Sanofi/Genzyme shift Campath to special distribution ahead of Lemtrada MS marketing
17:20 EDT 20 Aug 2012 | SCRIP
In anticipation of obtaining approval of their investigational multiple sclerosis drug Lemtrada (alemtuzumab), Paris-based Sanofi and its US unit Genzyme will only be making another version of the agent, sold as Campath, available to US patients.....
Original Article: Sanofi/Genzyme shift Campath to special distribution ahead of Lemtrada MS marketing
More From BioPortfolio on "Sanofi/Genzyme shift Campath to special distribution ahead of Lemtrada MS marketing"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
